WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC) (the “Company”) announced today that oral administration of its FluCide™ anti-influenza drug candidates provided clinically important disease protection in a lethal animal model of influenza infection. Moreover, the FluCide™ candidates were superior to oral oseltamivir (Tamiflu®, Roche), a current standard of care for influenza, in all parameters evaluated.
